BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
1. BioAtla plans to initiate Phase 3 study for Ozuriftamab vedotin. 2. FDA approved trial design for potential accelerated approval of Oz-V. 3. Oz-V shows 45% overall response rate in HPV+ OPSCC, outperforming standard treatments. 4. Strategic partnership expected to advance clinical development and commercialization. 5. CAB platform technology demonstrates promise for cancer treatments with lower toxicity.